Xencor Inc (XNCR) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 10 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026after close 35 8-K
Q2 FY2026Wed, Aug 5, 2026after close 36 8-K
Q1 FY2026Wed, May 6, 2026after close 36 8-K
Q4 FY2025Wed, Feb 25, 2026after close 56 8-K
Q3 FY2025Wed, Nov 5, 2025after close 36 8-K
Q2 FY2025Wed, Aug 6, 2025after close 37 8-K
Q1 FY2025Wed, May 7, 2025after close 37 8-K
Q4 FY2024Thu, Feb 27, 2025before open 58 8-K

What they guided beta

Q3 FY2026 "Document Exhibit 99.1 Xencor Reports Third Quarter 2026 Financial Results -- Updated results for XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma and outline of plans for potential registration-enabling development presented during ESMO -- -- Early dose-escalation data for plamotamab (CD20 x CD3) in rheumatoid arthritis to be presented during the ACR Convergence conference -- -- XmAb412 (TL1A x IL23p19) on track for initial healthy participant data in 1H27; XENITH-UC Phase 2b study of XmAb942 (anti-TL1A) in ulcerative colitis on track for primary endpoint analysis expected in " exhibit
Q3 FY2026 "We expect that the accelerating tempo of clinical development for XmAb819, and across our portfolio, may present multiple opportunities for continued momentum into the new year and throughout 2027." exhibit
Q3 FY2026 "Based on our plans, by the end of 2027 we anticipate XmAb819 will be the third XmAb 2+1 bispecific antibody to enter a potential registration-enabling study, following xaluritamig and ASP2138,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor." exhibit
Q3 FY2026 "“For our two TL1A-targeting development programs, enrollment in XENITH-UC, the global Phase 2b study of XmAb942, is on track for the primary endpoint analysis in the second half of 2027, and for our novel TL1A x IL23p19 bispecific, XmAb412, we plan to present healthy participant data in the first half of 2027.”" exhibit
Q3 FY2026 "The Phase 1 dose-escalation study of XmAb541 and XmAb808 is ongoing and expected to reach the combination’s target dose range in 2027." exhibit
Q2 FY2026 "Document Exhibit 99.1 Xencor Reports Second Quarter 2026 Financial Results -- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- -- XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week induction period expected in 2H27 -- -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study open for enrollment -- PASADENA, Calif.--August 5, 2026-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical com" exhibit
Q2 FY2026 "Wholly Owned Pipeline Overview XmAb819 (ENPP3 x CD3), a potential first-in-class, tumor-targeted, T-cell engaging XmAb® 2+1 bispecific antibody in development for patients with clear cell renal cell carcinoma and other tumors with high ENPP3 expression, including colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma Clear cell renal cell carcinoma (ccRCC) : On track to initiate a registration enabling study of XmAb819 as a monotherapy in advanced ccRCC during 2027." exhibit
Q2 FY2026 "The Phase 1 dose-escalation study of XmAb541 and XmAb808 is ongoing and expected to reach the combination’s target dose range in 2027." exhibit
Q2 FY2026 "Prioritization of the combination is anticipated to reduce projected overall XmAb541 program expense for 2027 and 2028." exhibit
Q2 FY2026 "Guidance: Based on current operating plans, Xencor expects to end 2026 with between $420 million and $440 million in cash, cash equivalents and marketable debt securities, and to have sufficient cash resources to fund research and development programs and operations through 2028." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/XNCR
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/XNCR

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

XNCR earnings date badge

HTML

<a href="https://veritasdata.dev/company/XNCR/"><img src="https://veritasdata.dev/embed/XNCR.svg" alt="XNCR earnings date" width="240" height="56"></a>

Markdown

[![XNCR earnings date](https://veritasdata.dev/embed/XNCR.svg)](https://veritasdata.dev/company/XNCR/)

Script

<script async src="https://veritasdata.dev/embed/XNCR.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/XNCR"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.